Larimar Therapeutics Inc. (LRMR)
| Bid | 2.84 |
| Market Cap | 182.16M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -80.6M |
| EPS (ttm) | -1.32 |
| PE Ratio (ttm) | -2.16 |
| Forward PE | -1.3 |
| Analyst | Buy |
| Ask | 2.92 |
| Volume | 2,844,897 |
| Avg. Volume (20D) | 858,321 |
| Open | 2.72 |
| Previous Close | 2.65 |
| Day's Range | 2.57 - 2.85 |
| 52-Week Range | 1.61 - 11.20 |
| Beta | 0.91 |
About LRMR
Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 1 clinical trial for the treatment of Friedreich's ataxia, a rare, progressive, and fatal genetic disease. The company is based in Bala Cynwyd, Pennsylvania....
Analyst Forecast
According to 9 analyst ratings, the average rating for LRMR stock is "Buy." The 12-month stock price forecast is $18, which is an increase of 532.69% from the latest price.
Stock Forecasts
3 months ago · seekingalpha.com
Larimar Therapeutics: Positive Friedreich's Ataxia Data Can Only Get BetterLarimar Therapeutics, Inc. reported initial positive data from phase 2 long-term OLE study using nomlabofusp for treatment of patients with Friedreich's Ataxia; Increase of tissue FXN protein levels f...